Gene

EGFR

epidermal growth factor receptor

Explore in graph →CI-GENE-00044375HGNC:3236 ENSG00000146648 NCBI 1956 CIViC Cancer geneApproved

Curated evidence

Clinical evidence (644)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 301–350 of 644 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
EGFR L747_P753>Q3
Gefitinib	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	C	Supports Sensitivity Response	—

Cohorts

Alteration frequency by cohort (195)

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

cbioportalObserved195 cohort rows (showing 50, sorted by frequency) · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
Lung Adenocarcinoma (MSK, 2021) luad_mskimpact_2021	Lung Adenocarcinoma	Ssm	183	186	98.4%

Literature

Linked publications (141)

25 per page, newest first.

pubmedPublishedShowing 76–100 of 141 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib.
· Clin Cancer Res · 2006 · PMID 17020982 · validated civic_curation pubmed
First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung.
· J Clin Oncol · 2012 · PMID 22370314 · validated civic_curation pubmed
EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib.
· Proc Natl Acad Sci U S A · 2004 · PMID 15329413 · validated civic_curation pubmed
Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer.

EGFR L747_S752del7
Afatinib	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	C	Supports Sensitivity Response	—	submitted	EID2154 A phase 3 study of 345 stage IIIB-IV lung adenocarcinoma patients, reported improved median progression free survival (13.6 months vs. 6.9 months, HR: 0.47, 95% CI: 0.34-0.65, P=0.001) in EGFR mutatio… (full text at CIViC) PMID 23816960 · Sequist et al., 2013 · Open in CIViC	civic
Erlotinib	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	C	Supports Sensitivity Response	—	submitted	EID3796 A study of five clinical trials reported that chemotherapy na�ve non-small cell lung cancer patients with EGFR sensitizing mutations (exon 19 deletion, L858R, L861Q, or G719X) treated with erlotinib o… (full text at CIViC) PMID 19671843 · Jackman et al., 2009 · Open in CIViC	civic
〃	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	C	Supports Sensitivity Response	—	submitted	EID3798 In a stage IV lung adenocarcinoma patient with choroidal metastasis harboring EGFR exon 19 deletion, EGFR exon 19 deletion was associated with sensitivity to erlotinib monotherapy. The patient was tre… (full text at CIViC) PMID 27569104 · Kocoglu et al., 2016 · Open in CIViC	civic
Gefitinib	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	C	Supports Sensitivity Response	—	submitted	EID2149 In a phase 3 clinical trial of Japanese NSCLC patients with EGFR mutations (n=230), patients treated with gefitinib were associated with improved progression free survival (10.8 months vs 5.4 months, … (full text at CIViC) PMID 20573926 · Maemondo et al., 2010 · Open in CIViC	civic
〃	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	C	Supports Sensitivity Response	—	submitted	EID2150 In a phase 3 clinical trial of Japanese NSCLC patients with EGFR mutations (n=177), patients treated with gefitinib were associated with improved progression free survival (9.2 months vs 6.3 months, H… (full text at CIViC) PMID 20022809 · Mitsudomi et al., 2010 · Open in CIViC	civic
〃	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	C	Supports Sensitivity Response	—	submitted	EID2151 EGFR exon 19 deletion mutations have been associated with increased sensitivity to first generation EGFR tyrosine kinase inhibitors, including erlotinib and gefitinib. In a Phase 2 clinical trial, lun… (full text at CIViC) PMID 15329413 · Pao et al., 2004 · Open in CIViC	civic
〃	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	D	Supports Sensitivity Response	—	rejected	EID2152 In an in vitro study using PC9 cells (EGFR exon 19 deletion), inhibition of cell viability was used as an assay to determine sensitivity to EGFR tyrosine kinase inhibitors. PC9 cells demonstrated an i… (full text at CIViC) PMID 24893891 · Cross et al., 2014 · Open in CIViC	civic

EGFR L747_S752del7

Afatinib

Lung Non-Small Cell CarcinomaCURATED_BROADER

Predictive

Supports Sensitivity Response

—

submitted

EID2154

A phase 3 study of 345 stage IIIB-IV lung adenocarcinoma patients, reported improved median progression free survival (13.6 months vs. 6.9 months, HR: 0.47, 95% CI: 0.34-0.65, P=0.001) in EGFR mutatio… (full text at CIViC)

PMID 23816960 · Sequist et al., 2013 · Open in CIViC

EGFR L858R18
(prognostic)	Lung Non-Small Cell CarcinomaCURATED_BROADER	Prognostic	B	Supports Better Outcome	3	accepted	EID347 Median survival of patients with EGFR L858R mutation is better than those with wild type EGFR. PMID 24662454 · Douillard et al., 2014 · Open in CIViC	civic
(oncogenic)	Lung Non-Small Cell CarcinomaCURATED_BROADER	Oncogenic	B	Supports Oncogenicity	3	submitted	EID13027 In this study, EGFR L858R was identified in multiple lung non-small cell carcinoma (NSCLC) cohorts, including 1 of 10 gefitinib-sensitive tumors, 3 of 7 erlotinib-sensitive tumors, 5 of 15 untreated … (full text at CIViC) PMID 15329413 · Pao et al., 2004 · Open in CIViC	civic
〃	Lung Non-Small Cell CarcinomaCURATED_BROADER	Oncogenic	D	Supports Oncogenicity	3	submitted	EID13024 In this study, the authors identified a somatic EGFR L858R mutation in two patients with gefitinib-responsive non-small cell lung cancer. Functional analysis of EGFR L858R expressed in Cos-7 cells dem… (full text at CIViC) PMID 15118073 · Lynch et al., 2004 · Open in CIViC	civic
〃	Lung Adenocarcinoma	Oncogenic	D	Supports Oncogenicity	3	submitted	EID13025 In this preclinical study, expression of EGFR L858R in Ba/F3 cells induced interleukin-3-independent proliferation, demonstrating ligand-independent cellular transformation. EGFR L858R was constitutiv… (full text at CIViC) PMID 16204070 · Jiang et al., 2005 · Open in CIViC	civic
〃	Lung Non-Small Cell CarcinomaCURATED_BROADER	Oncogenic	D	Supports Oncogenicity	3	submitted	EID13026 In this preclinical study, biochemical and structural analyses demonstrated that the EGFR L858R kinase exhibited approximately 50-fold greater catalytic activity than wild-type EGFR and adopted a cons… (full text at CIViC) PMID 17349580 · Yun et al., 2007 · Open in CIViC	civic
〃	Lung Non-Small Cell CarcinomaCURATED_BROADER	Oncogenic	D	Supports Oncogenicity	3	submitted	EID13029 Expression of EGFR L858R in non-small cell lung cancer (NSCLC) cell lines (H1299 and CL1-0) significantly increased cell invasion compared with wild-type EGFR, whereas EGFR L858R-specific knockdown re… (full text at CIViC) PMID 26338423 · Tsai et al., 2015 · Open in CIViC	civic
〃	Lung Non-Small Cell CarcinomaCURATED_BROADER	Oncogenic	D	Supports Oncogenicity	3	submitted	EID13030 Expression of EGFR L858R in stable cell models resulted in increased phosphorylation of EGFR tyrosine residues Y845, Y992, and Y1068 compared with wild-type EGFR following EGF stimulation. In both sta… (full text at CIViC) PMID 15284455 · Sordella et al., 2004 · Open in CIViC	civic
Afatinib	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	A	Supports Sensitivity Response	5	accepted	EID2997 Afatinib, an irreversible inhibitor of the ErbB family of tyrosine kinases has been approved in the US for the first-line treatment of patients with metastatic non-small-cell lung cancer (NSCLC) who h… (full text at CIViC) PMID 23982599 · Dungo et al., 2013 · Open in CIViC	civic
〃	Lung Adenocarcinoma	Predictive	B	Supports Sensitivity Response	4	accepted	EID879 A phase III clinical trial (NCT00949650) found that median progression free survival among patients with exon 19 deletions or L858R EGFR mutations (n = 308) was 13.6 months for afatinib and 6.9 months… (full text at CIViC) PMID 23816960 · Sequist et al., 2013 · Open in CIViC	civic
〃	Lung Adenocarcinoma	Predictive	B	Supports Sensitivity Response	4	accepted	EID982 Afatinib is an irreversible covalent inhibitor of EGFR (second generation). This Phase III clinical trial (LUX-Lung 6; NCT01121393) was performed in Asian patients with EGFR mutant advanced NSCLC. 364… (full text at CIViC) PMID 24439929 · Wu et al., 2014 · Open in CIViC	civic
〃	Lung Adenocarcinoma	Predictive	B	Supports Sensitivity Response	3	accepted	EID883 In a phase 2 study of patients with lung adenocarcinoma (stage IIIb with pleural effusion or stage IV) and EGFR mutations, treated with afatinib were assessed by objective response. 129 patients were … (full text at CIViC) PMID 22452895 · Yang et al., 2012 · Open in CIViC	civic
〃	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	C	Supports Sensitivity Response	—	submitted	EID2630 In a phase 2b/3 study of 585 stage IIIB-IV lung adenocarcinoma patients who had a previous round of EGFR-TKI treatment, archival material was available for 141 patients. EGFR mutational analysis revea… (full text at CIViC) PMID 22452896 · Miller et al., 2012 · Open in CIViC	civic
〃	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	D	Supports Sensitivity Response	2	accepted	EID968 Cells harboring L858R were sensitive to afatinib. This study performed drug response assays using five human NSCLC cell lines with various combinations of EGFR mutations. In order to directly compare … (full text at CIViC) PMID 26515464 · Hirano et al., 2015 · Open in CIViC	civic
〃	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	D	Supports Sensitivity Response	2	accepted	EID2629 In an in vitro study using NCI-H1666 cells (wildtype EGFR) and NCI-H3255 cells (EGFR-L858R), inhibition of cell growth was used as an assay to determine sensitivity to irreversible tyrosine kinase inh… (full text at CIViC) PMID 18408761 · Li et al., 2008 · Open in CIViC	civic
Canertinib	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	D	Supports Sensitivity Response	3	accepted	EID2631 In an in vitro study using NCI-H1666 cells (wildtype EGFR) and NCI-H3255 cells (EGFR-L858R), inhibition of cell growth was used as an assay to determine sensitivity to irreversible tyrosine kinase inh… (full text at CIViC) PMID 18408761 · Li et al., 2008 · Open in CIViC	civic
Cetuximab	Lung Adenocarcinoma	Predictive	D	Does Not Support Sensitivity Response	3	accepted	EID4292 In an in vitro study, Ba/F3 cell line expressing EGFR L858R did not show sensitivity to cetuximab treatment, while cells expressing EGFR-RAD51 fusion were sensitive. Sensitivity was determined by asse… (full text at CIViC) PMID 27102076 · Konduri et al., 2016 · Open in CIViC	civic
Crizotinib	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	C	Supports Resistance	3	accepted	EID4288 This study analyzed patients with non small cell lung cancer (NSCLC) who were positive for EML4-ALK fusions (ALK+) and progressed on crizotinib monotherapy. One patient was biopsied twice following cr… (full text at CIViC) PMID 22235099 · Doebele et al., 2012 · Open in CIViC	civic
Dacomitinib	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	B	Supports Sensitivity Response	5	accepted	EID4860 The authors pooled patients with exon 19 deletion and L858R EGFR (Exon 21) mutations from both studies (The ARCHER 1009 (NCT01360554) and A7471028 (NCT00769067)) to compare the efficacy of dacomitinib… (full text at CIViC) PMID 26768165 · Ramalingam et al., 2016 · Open in CIViC	civic